- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Tumor Biomarker Test market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Tumor Biomarker Test market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Lung cancer accounting for % of the Tumor Biomarker Test global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Prostate Specific Antigen Tests segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Tumor Biomarker Test include Abbott Laboratories, Inc., Agilent Technologies, AstraZeneca, Becton Dickinson & Co., and Biocept Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Tumor Biomarker Test market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Prostate Specific Antigen Tests
CTC Tests
Alpha-Fetoprotein (AFP) Tests
CA Test
HER2 Tests
BRCA Test
Anaplastic Lymphoma Kinase (ALK) Tests
EGFR Mutation Tests
KRAS Test
Others
Market segment by Application, can be divided into
Lung cancer
Breast cancer
Colorectal
Prostate Cancer
Blood Cancer
Market segment by players, this report covers
Abbott Laboratories, Inc.
Agilent Technologies
AstraZeneca
Becton Dickinson & Co.
Biocept Inc.
Cancer Genetics Inc.
Danaher Corporation
Foundation Medicine Inc.
Illumina Inc.
LabCorp Of America Holdings
Luminex Corporation
Myriad Genetics Inc.
NanoString Technologies Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Tumor Biomarker Test product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Tumor Biomarker Test, with revenue, gross margin and global market share of Tumor Biomarker Test from 2019 to 2022.
Chapter 3, the Tumor Biomarker Test competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Tumor Biomarker Test market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Tumor Biomarker Test research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Tumor Biomarker Test
1.2 Classification of Tumor Biomarker Test by Type
1.2.1 Overview: Global Tumor Biomarker Test Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Tumor Biomarker Test Revenue Market Share by Type in 2021
1.2.3 Prostate Specific Antigen Tests
1.2.4 CTC Tests
1.2.5 Alpha-Fetoprotein (AFP) Tests
1.2.6 CA Test
1.2.7 HER2 Tests
1.2.8 BRCA Test
1.2.9 Anaplastic Lymphoma Kinase (ALK) Tests
1.2.10 EGFR Mutation Tests
1.2.11 KRAS Test
1.2.12 Others
1.3 Global Tumor Biomarker Test Market by Application
1.3.1 Overview: Global Tumor Biomarker Test Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Lung cancer
1.3.3 Breast cancer
1.3.4 Colorectal
1.3.5 Prostate Cancer
1.3.6 Blood Cancer
1.4 Global Tumor Biomarker Test Market Size & Forecast
1.5 Global Tumor Biomarker Test Market Size and Forecast by Region
1.5.1 Global Tumor Biomarker Test Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Tumor Biomarker Test Market Size by Region, (2017-2022)
1.5.3 North America Tumor Biomarker Test Market Size and Prospect (2017-2028)
1.5.4 Europe Tumor Biomarker Test Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Tumor Biomarker Test Market Size and Prospect (2017-2028)
1.5.6 South America Tumor Biomarker Test Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Tumor Biomarker Test Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Tumor Biomarker Test Market Drivers
1.6.2 Tumor Biomarker Test Market Restraints
1.6.3 Tumor Biomarker Test Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 Abbott Laboratories, Inc.
2.1.1 Abbott Laboratories, Inc. Details
2.1.2 Abbott Laboratories, Inc. Major Business
2.1.3 Abbott Laboratories, Inc. Tumor Biomarker Test Product and Solutions
2.1.4 Abbott Laboratories, Inc. Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Abbott Laboratories, Inc. Recent Developments and Future Plans
2.2 Agilent Technologies
2.2.1 Agilent Technologies Details
2.2.2 Agilent Technologies Major Business
2.2.3 Agilent Technologies Tumor Biomarker Test Product and Solutions
2.2.4 Agilent Technologies Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Agilent Technologies Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Tumor Biomarker Test Product and Solutions
2.3.4 AstraZeneca Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Becton Dickinson & Co.
2.4.1 Becton Dickinson & Co. Details
2.4.2 Becton Dickinson & Co. Major Business
2.4.3 Becton Dickinson & Co. Tumor Biomarker Test Product and Solutions
2.4.4 Becton Dickinson & Co. Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Becton Dickinson & Co. Recent Developments and Future Plans
2.5 Biocept Inc.
2.5.1 Biocept Inc. Details
2.5.2 Biocept Inc. Major Business
2.5.3 Biocept Inc. Tumor Biomarker Test Product and Solutions
2.5.4 Biocept Inc. Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Biocept Inc. Recent Developments and Future Plans
2.6 Cancer Genetics Inc.
2.6.1 Cancer Genetics Inc. Details
2.6.2 Cancer Genetics Inc. Major Business
2.6.3 Cancer Genetics Inc. Tumor Biomarker Test Product and Solutions
2.6.4 Cancer Genetics Inc. Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Cancer Genetics Inc. Recent Developments and Future Plans
2.7 Danaher Corporation
2.7.1 Danaher Corporation Details
2.7.2 Danaher Corporation Major Business
2.7.3 Danaher Corporation Tumor Biomarker Test Product and Solutions
2.7.4 Danaher Corporation Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Danaher Corporation Recent Developments and Future Plans
2.8 Foundation Medicine Inc.
2.8.1 Foundation Medicine Inc. Details
2.8.2 Foundation Medicine Inc. Major Business
2.8.3 Foundation Medicine Inc. Tumor Biomarker Test Product and Solutions
2.8.4 Foundation Medicine Inc. Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Foundation Medicine Inc. Recent Developments and Future Plans
2.9 Illumina Inc.
2.9.1 Illumina Inc. Details
2.9.2 Illumina Inc. Major Business
2.9.3 Illumina Inc. Tumor Biomarker Test Product and Solutions
2.9.4 Illumina Inc. Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Illumina Inc. Recent Developments and Future Plans
2.10 LabCorp Of America Holdings
2.10.1 LabCorp Of America Holdings Details
2.10.2 LabCorp Of America Holdings Major Business
2.10.3 LabCorp Of America Holdings Tumor Biomarker Test Product and Solutions
2.10.4 LabCorp Of America Holdings Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 LabCorp Of America Holdings Recent Developments and Future Plans
2.11 Luminex Corporation
2.11.1 Luminex Corporation Details
2.11.2 Luminex Corporation Major Business
2.11.3 Luminex Corporation Tumor Biomarker Test Product and Solutions
2.11.4 Luminex Corporation Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Luminex Corporation Recent Developments and Future Plans
2.12 Myriad Genetics Inc.
2.12.1 Myriad Genetics Inc. Details
2.12.2 Myriad Genetics Inc. Major Business
2.12.3 Myriad Genetics Inc. Tumor Biomarker Test Product and Solutions
2.12.4 Myriad Genetics Inc. Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Myriad Genetics Inc. Recent Developments and Future Plans
2.13 NanoString Technologies Inc.
2.13.1 NanoString Technologies Inc. Details
2.13.2 NanoString Technologies Inc. Major Business
2.13.3 NanoString Technologies Inc. Tumor Biomarker Test Product and Solutions
2.13.4 NanoString Technologies Inc. Tumor Biomarker Test Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 NanoString Technologies Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Tumor Biomarker Test Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Tumor Biomarker Test Players Market Share in 2021
3.2.2 Top 10 Tumor Biomarker Test Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Tumor Biomarker Test Players Head Office, Products and Services Provided
3.4 Tumor Biomarker Test Mergers & Acquisitions
3.5 Tumor Biomarker Test New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Tumor Biomarker Test Revenue and Market Share by Type (2017-2022)
4.2 Global Tumor Biomarker Test Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Tumor Biomarker Test Revenue Market Share by Application (2017-2022)
5.2 Global Tumor Biomarker Test Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Tumor Biomarker Test Revenue by Type (2017-2028)
6.2 North America Tumor Biomarker Test Revenue by Application (2017-2028)
6.3 North America Tumor Biomarker Test Market Size by Country
6.3.1 North America Tumor Biomarker Test Revenue by Country (2017-2028)
6.3.2 United States Tumor Biomarker Test Market Size and Forecast (2017-2028)
6.3.3 Canada Tumor Biomarker Test Market Size and Forecast (2017-2028)
6.3.4 Mexico Tumor Biomarker Test Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Tumor Biomarker Test Revenue by Type (2017-2028)
7.2 Europe Tumor Biomarker Test Revenue by Application (2017-2028)
7.3 Europe Tumor Biomarker Test Market Size by Country
7.3.1 Europe Tumor Biomarker Test Revenue by Country (2017-2028)
7.3.2 Germany Tumor Biomarker Test Market Size and Forecast (2017-2028)
7.3.3 France Tumor Biomarker Test Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Tumor Biomarker Test Market Size and Forecast (2017-2028)
7.3.5 Russia Tumor Biomarker Test Market Size and Forecast (2017-2028)
7.3.6 Italy Tumor Biomarker Test Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Tumor Biomarker Test Revenue by Type (2017-2028)
8.2 Asia-Pacific Tumor Biomarker Test Revenue by Application (2017-2028)
8.3 Asia-Pacific Tumor Biomarker Test Market Size by Region
8.3.1 Asia-Pacific Tumor Biomarker Test Revenue by Region (2017-2028)
8.3.2 China Tumor Biomarker Test Market Size and Forecast (2017-2028)
8.3.3 Japan Tumor Biomarker Test Market Size and Forecast (2017-2028)
8.3.4 South Korea Tumor Biomarker Test Market Size and Forecast (2017-2028)
8.3.5 India Tumor Biomarker Test Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Tumor Biomarker Test Market Size and Forecast (2017-2028)
8.3.7 Australia Tumor Biomarker Test Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Tumor Biomarker Test Revenue by Type (2017-2028)
9.2 South America Tumor Biomarker Test Revenue by Application (2017-2028)
9.3 South America Tumor Biomarker Test Market Size by Country
9.3.1 South America Tumor Biomarker Test Revenue by Country (2017-2028)
9.3.2 Brazil Tumor Biomarker Test Market Size and Forecast (2017-2028)
9.3.3 Argentina Tumor Biomarker Test Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Tumor Biomarker Test Revenue by Type (2017-2028)
10.2 Middle East & Africa Tumor Biomarker Test Revenue by Application (2017-2028)
10.3 Middle East & Africa Tumor Biomarker Test Market Size by Country
10.3.1 Middle East & Africa Tumor Biomarker Test Revenue by Country (2017-2028)
10.3.2 Turkey Tumor Biomarker Test Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Tumor Biomarker Test Market Size and Forecast (2017-2028)
10.3.4 UAE Tumor Biomarker Test Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Tumor Biomarker Test Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Tumor Biomarker Test Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Tumor Biomarker Test Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Tumor Biomarker Test Revenue (USD Million) by Region (2017-2022)
Table 5. Global Tumor Biomarker Test Revenue Market Share by Region (2023-2028)
Table 6. Abbott Laboratories, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Abbott Laboratories, Inc. Major Business
Table 8. Abbott Laboratories, Inc. Tumor Biomarker Test Product and Solutions
Table 9. Abbott Laboratories, Inc. Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Agilent Technologies Corporate Information, Head Office, and Major Competitors
Table 11. Agilent Technologies Major Business
Table 12. Agilent Technologies Tumor Biomarker Test Product and Solutions
Table 13. Agilent Technologies Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 15. AstraZeneca Major Business
Table 16. AstraZeneca Tumor Biomarker Test Product and Solutions
Table 17. AstraZeneca Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Becton Dickinson & Co. Corporate Information, Head Office, and Major Competitors
Table 19. Becton Dickinson & Co. Major Business
Table 20. Becton Dickinson & Co. Tumor Biomarker Test Product and Solutions
Table 21. Becton Dickinson & Co. Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Biocept Inc. Corporate Information, Head Office, and Major Competitors
Table 23. Biocept Inc. Major Business
Table 24. Biocept Inc. Tumor Biomarker Test Product and Solutions
Table 25. Biocept Inc. Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Cancer Genetics Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Cancer Genetics Inc. Major Business
Table 28. Cancer Genetics Inc. Tumor Biomarker Test Product and Solutions
Table 29. Cancer Genetics Inc. Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Danaher Corporation Corporate Information, Head Office, and Major Competitors
Table 31. Danaher Corporation Major Business
Table 32. Danaher Corporation Tumor Biomarker Test Product and Solutions
Table 33. Danaher Corporation Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Foundation Medicine Inc. Corporate Information, Head Office, and Major Competitors
Table 35. Foundation Medicine Inc. Major Business
Table 36. Foundation Medicine Inc. Tumor Biomarker Test Product and Solutions
Table 37. Foundation Medicine Inc. Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Illumina Inc. Corporate Information, Head Office, and Major Competitors
Table 39. Illumina Inc. Major Business
Table 40. Illumina Inc. Tumor Biomarker Test Product and Solutions
Table 41. Illumina Inc. Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. LabCorp Of America Holdings Corporate Information, Head Office, and Major Competitors
Table 43. LabCorp Of America Holdings Major Business
Table 44. LabCorp Of America Holdings Tumor Biomarker Test Product and Solutions
Table 45. LabCorp Of America Holdings Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Luminex Corporation Corporate Information, Head Office, and Major Competitors
Table 47. Luminex Corporation Major Business
Table 48. Luminex Corporation Tumor Biomarker Test Product and Solutions
Table 49. Luminex Corporation Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Myriad Genetics Inc. Corporate Information, Head Office, and Major Competitors
Table 51. Myriad Genetics Inc. Major Business
Table 52. Myriad Genetics Inc. Tumor Biomarker Test Product and Solutions
Table 53. Myriad Genetics Inc. Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. NanoString Technologies Inc. Corporate Information, Head Office, and Major Competitors
Table 55. NanoString Technologies Inc. Major Business
Table 56. NanoString Technologies Inc. Tumor Biomarker Test Product and Solutions
Table 57. NanoString Technologies Inc. Tumor Biomarker Test Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Global Tumor Biomarker Test Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 59. Global Tumor Biomarker Test Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 60. Breakdown of Tumor Biomarker Test by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Tumor Biomarker Test Players Head Office, Products and Services Provided
Table 62. Tumor Biomarker Test Mergers & Acquisitions in the Past Five Years
Table 63. Tumor Biomarker Test New Entrants and Expansion Plans
Table 64. Global Tumor Biomarker Test Revenue (USD Million) by Type (2017-2022)
Table 65. Global Tumor Biomarker Test Revenue Share by Type (2017-2022)
Table 66. Global Tumor Biomarker Test Revenue Forecast by Type (2023-2028)
Table 67. Global Tumor Biomarker Test Revenue by Application (2017-2022)
Table 68. Global Tumor Biomarker Test Revenue Forecast by Application (2023-2028)
Table 69. North America Tumor Biomarker Test Revenue by Type (2017-2022) & (USD Million)
Table 70. North America Tumor Biomarker Test Revenue by Type (2023-2028) & (USD Million)
Table 71. North America Tumor Biomarker Test Revenue by Application (2017-2022) & (USD Million)
Table 72. North America Tumor Biomarker Test Revenue by Application (2023-2028) & (USD Million)
Table 73. North America Tumor Biomarker Test Revenue by Country (2017-2022) & (USD Million)
Table 74. North America Tumor Biomarker Test Revenue by Country (2023-2028) & (USD Million)
Table 75. Europe Tumor Biomarker Test Revenue by Type (2017-2022) & (USD Million)
Table 76. Europe Tumor Biomarker Test Revenue by Type (2023-2028) & (USD Million)
Table 77. Europe Tumor Biomarker Test Revenue by Application (2017-2022) & (USD Million)
Table 78. Europe Tumor Biomarker Test Revenue by Application (2023-2028) & (USD Million)
Table 79. Europe Tumor Biomarker Test Revenue by Country (2017-2022) & (USD Million)
Table 80. Europe Tumor Biomarker Test Revenue by Country (2023-2028) & (USD Million)
Table 81. Asia-Pacific Tumor Biomarker Test Revenue by Type (2017-2022) & (USD Million)
Table 82. Asia-Pacific Tumor Biomarker Test Revenue by Type (2023-2028) & (USD Million)
Table 83. Asia-Pacific Tumor Biomarker Test Revenue by Application (2017-2022) & (USD Million)
Table 84. Asia-Pacific Tumor Biomarker Test Revenue by Application (2023-2028) & (USD Million)
Table 85. Asia-Pacific Tumor Biomarker Test Revenue by Region (2017-2022) & (USD Million)
Table 86. Asia-Pacific Tumor Biomarker Test Revenue by Region (2023-2028) & (USD Million)
Table 87. South America Tumor Biomarker Test Revenue by Type (2017-2022) & (USD Million)
Table 88. South America Tumor Biomarker Test Revenue by Type (2023-2028) & (USD Million)
Table 89. South America Tumor Biomarker Test Revenue by Application (2017-2022) & (USD Million)
Table 90. South America Tumor Biomarker Test Revenue by Application (2023-2028) & (USD Million)
Table 91. South America Tumor Biomarker Test Revenue by Country (2017-2022) & (USD Million)
Table 92. South America Tumor Biomarker Test Revenue by Country (2023-2028) & (USD Million)
Table 93. Middle East & Africa Tumor Biomarker Test Revenue by Type (2017-2022) & (USD Million)
Table 94. Middle East & Africa Tumor Biomarker Test Revenue by Type (2023-2028) & (USD Million)
Table 95. Middle East & Africa Tumor Biomarker Test Revenue by Application (2017-2022) & (USD Million)
Table 96. Middle East & Africa Tumor Biomarker Test Revenue by Application (2023-2028) & (USD Million)
Table 97. Middle East & Africa Tumor Biomarker Test Revenue by Country (2017-2022) & (USD Million)
Table 98. Middle East & Africa Tumor Biomarker Test Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Tumor Biomarker Test Picture
Figure 2. Global Tumor Biomarker Test Revenue Market Share by Type in 2021
Figure 3. Prostate Specific Antigen Tests
Figure 4. CTC Tests
Figure 5. Alpha-Fetoprotein (AFP) Tests
Figure 6. CA Test
Figure 7. HER2 Tests
Figure 8. BRCA Test
Figure 9. Anaplastic Lymphoma Kinase (ALK) Tests
Figure 10. EGFR Mutation Tests
Figure 11. KRAS Test
Figure 12. Others
Figure 13. Tumor Biomarker Test Revenue Market Share by Application in 2021
Figure 14. Lung cancer Picture
Figure 15. Breast cancer Picture
Figure 16. Colorectal Picture
Figure 17. Prostate Cancer Picture
Figure 18. Blood Cancer Picture
Figure 19. Global Tumor Biomarker Test Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 20. Global Tumor Biomarker Test Revenue and Forecast (2017-2028) & (USD Million)
Figure 21. Global Tumor Biomarker Test Revenue Market Share by Region (2017-2028)
Figure 22. Global Tumor Biomarker Test Revenue Market Share by Region in 2021
Figure 23. North America Tumor Biomarker Test Revenue (USD Million) and Growth Rate (2017-2028)
Figure 24. Europe Tumor Biomarker Test Revenue (USD Million) and Growth Rate (2017-2028)
Figure 25. Asia-Pacific Tumor Biomarker Test Revenue (USD Million) and Growth Rate (2017-2028)
Figure 26. South America Tumor Biomarker Test Revenue (USD Million) and Growth Rate (2017-2028)
Figure 27. Middle East and Africa Tumor Biomarker Test Revenue (USD Million) and Growth Rate (2017-2028)
Figure 28. Tumor Biomarker Test Market Drivers
Figure 29. Tumor Biomarker Test Market Restraints
Figure 30. Tumor Biomarker Test Market Trends
Figure 31. Abbott Laboratories, Inc. Recent Developments and Future Plans
Figure 32. Agilent Technologies Recent Developments and Future Plans
Figure 33. AstraZeneca Recent Developments and Future Plans
Figure 34. Becton Dickinson & Co. Recent Developments and Future Plans
Figure 35. Biocept Inc. Recent Developments and Future Plans
Figure 36. Cancer Genetics Inc. Recent Developments and Future Plans
Figure 37. Danaher Corporation Recent Developments and Future Plans
Figure 38. Foundation Medicine Inc. Recent Developments and Future Plans
Figure 39. Illumina Inc. Recent Developments and Future Plans
Figure 40. LabCorp Of America Holdings Recent Developments and Future Plans
Figure 41. Luminex Corporation Recent Developments and Future Plans
Figure 42. Myriad Genetics Inc. Recent Developments and Future Plans
Figure 43. NanoString Technologies Inc. Recent Developments and Future Plans
Figure 44. Global Tumor Biomarker Test Revenue Share by Players in 2021
Figure 45. Tumor Biomarker Test Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 46. Global Top 3 Players Tumor Biomarker Test Revenue Market Share in 2021
Figure 47. Global Top 10 Players Tumor Biomarker Test Revenue Market Share in 2021
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 49. Global Tumor Biomarker Test Revenue Share by Type in 2021
Figure 50. Global Tumor Biomarker Test Market Share Forecast by Type (2023-2028)
Figure 51. Global Tumor Biomarker Test Revenue Share by Application in 2021
Figure 52. Global Tumor Biomarker Test Market Share Forecast by Application (2023-2028)
Figure 53. North America Tumor Biomarker Test Sales Market Share by Type (2017-2028)
Figure 54. North America Tumor Biomarker Test Sales Market Share by Application (2017-2028)
Figure 55. North America Tumor Biomarker Test Revenue Market Share by Country (2017-2028)
Figure 56. United States Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Canada Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Mexico Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Europe Tumor Biomarker Test Sales Market Share by Type (2017-2028)
Figure 60. Europe Tumor Biomarker Test Sales Market Share by Application (2017-2028)
Figure 61. Europe Tumor Biomarker Test Revenue Market Share by Country (2017-2028)
Figure 62. Germany Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. France Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. United Kingdom Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Russia Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Italy Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Asia-Pacific Tumor Biomarker Test Sales Market Share by Type (2017-2028)
Figure 68. Asia-Pacific Tumor Biomarker Test Sales Market Share by Application (2017-2028)
Figure 69. Asia-Pacific Tumor Biomarker Test Revenue Market Share by Region (2017-2028)
Figure 70. China Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Japan Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. South Korea Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. India Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Southeast Asia Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Australia Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South America Tumor Biomarker Test Sales Market Share by Type (2017-2028)
Figure 77. South America Tumor Biomarker Test Sales Market Share by Application (2017-2028)
Figure 78. South America Tumor Biomarker Test Revenue Market Share by Country (2017-2028)
Figure 79. Brazil Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Argentina Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Middle East and Africa Tumor Biomarker Test Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Tumor Biomarker Test Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Tumor Biomarker Test Revenue Market Share by Country (2017-2028)
Figure 84. Turkey Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Saudi Arabia Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. UAE Tumor Biomarker Test Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
